|


Policies
& Procedures on Research Involving
Human Subjects
Statement
of Ethical Responsibility for Research Involving Human Subjects
New
School faculty and staff engaged in research or supervising student
research projects must be aware of their responsibilities for ethical
conduct in any project involving the use of human subjects. Faculty
and staff are responsible for research done by students under their
supervision with respect to these matters. Each research design
must be examined for possible risk to subjects. If even minor risk
of physical, psychological, sociological or other harm may be involved,
the faculty or staff member must consult with the University Institutional
Review Board (IRB) to determine that:
1.
The risks to the subject are so outweighed by the sum of the benefit
to the subject and the importance of the knowledge to be gained
as to warrant a decision to allow the subject to accept these risks;
2.
The rights and welfare of any such subjects will be adequately protected;
3.
Legally effective informed consent will be obtained by adequate
and appropriate methods in accordance with the provisions of this
part; and
4.
The conduct of the activity will be reviewed at timely intervals
and no less than once per year.
In
addition to questions of risk and informed consent, the subjects
rights of privacy must be protected.
If
a faculty or staff member has any doubts regarding the ethics of
a project or steps taken to protect human subjects, h/she should
refer them to the IRB. In any case, the IRB should be informed of
all research projects involving human subjects.
The
New School University Institutional Review Board (IRB) is the official
oversight committee for the protection of human subjects in research.
It functions under a Multiple Project Assurance (MPA-1445) granted
by the Office for Protection from Research Risks (OPRR) of the Department
of Health and Human Services (DHHS).
The
IRB reviews each applicable research proposal and related materials,
including informed consent documents. The IRB has the responsibility
and authority to approve, require modification of, or disapprove
any research activity involving human subjects. Research protocols
will be reviewed not less than every 12 months and perhaps more
frequently if required by the IRB on the basis of degree of risk
to subjects, amendments made to the protocol, or adverse events
reported.
IRB
review and approval are independent of the initial endorsement by
the institutional official of the extramural research proposal.
Dr.
Marcel Kinsbourne is the IRB Chair. Students should contact IRB@newschool.edu
with their applications.
Return to Table of Contents
General
Requirements For Informed Consent*
(45 CFR ß46.116)
Except
as provided elsewhere in 45 CFR 46, no investigator may involve
a human being as a subject in research covered by this policy unless
the investigator has obtained the legally effective informed consent
of the subject or the subjects' legally authorized representative.
An investigator shall seek such consent only under circumstances
that provide the prospective subject or the representative sufficient
opportunity to consider whether or not to participate and that minimize
the possibility of coercion or undue influence. The information
that is given to the subject or the representative shall be in language
understandable to the subject or the representative. No informed
consent, whether oral or written, may include any exculpatory language
through which the subject or the representative is made to waive
or appear to waive any of the subjects' legal rights, or releases
or appears to release the investigator, the sponsor, the institution
or its agents from liability for negligence.
(a)
Basic elements of informed consent. In seeking informed consent
the following information shall be provided to each subject:
(1)
a statement that the study involves research, an explanation of
the purposes of the research and the expected duration of the subject’s
participation, a description of the procedures to be followed, and
identification of any procedures which are experimental;
(2)
a description of any reasonably foreseeable risks or discomforts
to the subject;
(3)
a description of any benefits to the subject or to others which
may reasonably be expected from the research;
(4)
a disclosure of appropriate alternative procedures or courses of
treatment, if any, that might be advantageous to the subject;
(5)
a statement describing the extent, if any, to which confidentiality
of records identifying the subject will be maintained;
(6)
for research involving more than minimal risk, an explanation as
to whether any compensation and an explanation as to whether any
medical treatments are available if injury occurs and, if so, what
they consist of, or where further information may be obtained;
(7)
an explanation of whom to contact for answers to pertinent questions
about the research and research subjects' rights, and whom to contact
in the event of a research-related injury to the subject; and
(8)
a statement that participation is voluntary, refusal to participate
will involve no penalty of loss of benefits to which the subject
is otherwise entitled, and the subject may discontinue participation
at any time without penalty or loss of benefits to which the subject
is otherwise entitled.
(b)
Additional elements of informed consent. When appropriate, one or
more of the following elements of information shall also be provided
to each subject:
(1)
a statement that the particular treatment or procedure may involve
risks to the subject (or to the embryo or fetus, if the subject
is or may become pregnant) which are currently unforeseeable;
(2)
anticipated circumstances under which the subjects' participation
may be terminated by the investigator without regard to the subject's
consent;
(3)
any additional costs to the subject that may result from participation
in the research;
(4)
the consequences of a subjects' decision to withdraw from the research
and procedures for orderly termination of participation by the subject;
(5)
a statement that significant new findings developed during the course
of the research which may relate to the subjects' willingness to
continue participation will be provided to the subject; and
(6)
the approximate number of subjects involved in the study. Documentation
of Informed Consent (45 CFR ß46.117)
(a)
Except as provided in paragraph (c) of this section, informed consent
shall be documented by the use of a written consent form approved
by the IRB and signed by the subject or the subjects' legally authorized
representative. A copy shall be given to the person signing the
form.
(b)
Except as provided in paragraph (c) of this section, the consent
form may be either of the following:
(1)
A written document that embodies the elements of informed consent
required by ß46.116. This form may be read to the subject or the
subjects' legally authorized representative, but in any event, the
investigator shall give either the subject or the representative
adequate opportunity to read it before it is signed; or
(2)
A short form written consent document stating that the elements
of informed consent required by ß46.116 have been presented orally
to the subject or the subjects' legally authorized representative.
When this method is used, there shall be a witness to the oral presentation.
Also, the IRB shall approve a written summary of what is to be said
to the subject or the representative. Only the short form itself
is to be signed by the subject or the representative. However, the
witness shall sign both the short form and a copy of the summary,
and the person actually obtaining consent shall sign a copy of the
summary. A copy of the summary shall be given to the subject or
the representative, in addition to a copy of the short form.
Return to Table of Contents
Modification
of Informed Consent Procedures
Modifications
of any of the informed consent procedures must be approved by the
IRB in the minutes signed by the Chair. Granting of permission to
use modified procedures imposes additional responsibility upon the
IRB and the University to establish that the risk to any subject
is minimal, that use of either of the informed consent procedures
would invalidate objectives of considerable immediate importance,
and that any reasonable alternative means for attaining these objectives
would be less advantageous to the subject.
Guidelines
For Preparing An Informed Consent Form
An
informed consent form requires a fair and proper explanation of
all of the basic elements of informed consent listed in (a)(1)-(a)(8)
above. When appropriate, elements from (b)(1)-(b)(6) should also
be included. The order of explanations or the use of words should
be adapted to the nature of each study and subject.
In
addition, the agreement of consent, written or oral, should include
no exculpatory language through which the subject is made to waive
or appear to waive his/her legal rights or release the institution
or appear to release the institution or its agents from liability
for negligence.
The
name and telephone number of the project director should be clearly
indicated on the consent form as should the name and telephone number
of Dr. Marcel Kinsbourne, Chair, Human Subjects Committee, 212-229-5727
Ext. 3103, for questions about research subjects' rights and for
research-related injuries and complaints.
A statement
that the subject has been given a copy of the consent form to keep
should also be included. The form should include an authorization
section, for example:
I,
the undersigned, have understood the above explanation and give
consent to my voluntary participation in
(Dr./Mr./Ms.)_______________________________
research project.
Date________________
Location_____________
________________________________________Signature
of subject
________________________________________Signature
of legal representative (if applicable)
________________________________________Signature
of person obtaining consent
________________________________________Signature
of witness (if applicable) * Source: Protection of Human Subjects,
Title
45, Code of Federal Regualtions, Part 46. Revised June
Return to Table of Contents
Instructions
and Application for Submitting Research Proposals to the Institutional
Review Board (MSW)
Beginning
in September, 2000, the IRB will be chaired by Dr. Marcel Kinsbourne,
Professor, Psychology at The New School for Social Research. Please contact
him with any questions and to submit the IRB Application (MSW Format).
Dr.
Marcel Kinsbourne
Professor, Psychology Chair,
New School University Institutional Review Board
The New School for Social Research
Albert List Academic Center
65 Fifth Avenue/Room 240
New York, NY 10011
212-229-5727 Ext. 3103
kinsboum@newschool.edu
Informed
Consent Checklist - Basic and Additional Elements
A Statement
that the study involves research
An
explanation of the purposes of the research The expected duration
of the subject's participation
A description
of the procedures to be followed Identification of any procedures
which are experimental
A description
of any reasonably foreseeable risks or discomforts to the Subject.
A description
of any benefits to the subject or to others which may reasonably
be expected from the research
A disclosure
of appropriate alternative procedures or courses of treatment, if
any, that might be advantageous to the subject
A statement
describing the extent, if any, to which confidentiality of records
identifying the subject will be maintained For research involving
more than minimal risk, an explanation as to whether any compensation,
and an explanation as to whether any medical treatments are available,
if injury occurs and, if so, what they consist of, or where further
information may be obtained
( )
Research Questions
An
explanation of whom to contact for answers to pertinent questions
about the research and research subjects' rights, and whom to contact
in the event of a research-related injury to the subject.
( )
Rights Questions
( )
Injury Questions
A statement
that participation is voluntary, refusal to participate will involve
no penalty or loss of benefits to which the subject is otherwise
entitled, and the subject may discontinue participation at any time
without penalty or loss of benefits, to which the subject is otherwise
entitled
Additional
elements, as appropriate
A statement
that the particular treatment or procedure may involve risks to
the subject (or to the embryo or fetus, if the subject is or may
become pregnant), which are currently unforeseeable Anticipated
circumstances under which the subject's participation may be terminated
by the investigator without regard to the subject's consent
Any
additional costs to the subject that may result from participation
in the research
The
consequences of a subject's decision to withdraw from the research
and procedures for orderly termination of participation by the subject
A statement
that significant new findings developed during the course of the
research, which may relate to the subject's willingness to continue
participation, will be provided to the subject The approximate number
of subjects involved in the study
§46.117
Documentation
of Informed Consent Checklist a. Except as provided in paragraph
"c" of this section, informed consent shall be documented
by the use of a written consent form approved by the IRB, and signed
by the subject or the subject's legally authorized representative.
A copy shall be given to the person signing the form.
WRITTEN
The
consent form may be either of the following:
1.
A written consent document that embodies the elements of informed
consent required by §46.116. This form may be read to the subject
or the subject's legally authorized representative, but in any event,
the investigator should give either the subject or the representative
adequate opportunity to read it before it is signed.
DONE
ORALLY
2.
A short form written consent document, stating that the elements
of informed consent required by §46.116 have been presented orally
to the subject or the subject's legally authorized representative.
When this method is used, there shall be a witness to the oral presentation.
Also, the IRB shall approve a written summary of what is to be said
to the subject or the representative. Only the short form itself
is to be signed by the subject or the representative. However, the
witness shall sign both the short form and a copy of the summary,
and the person actually obtaining consent shall sign a copy of the
summary. A copy of the summary shall be given to the subject or
the representative, in addition to a copy of the short form.
WAIVER
of req't for signed formc.
An
IRB may waive the requirement for the investigator to obtain a signed
consent form for some or all subjects, if it finds either:
1.
That the only record linking the subject and the research would
be the consent document, and the principal risk would be potential
harm resulting from a breach of confidentiality. Each subject will
be asked whether the subject wants documentation linking the subject
with the research, and the subject's wishes will govern; or
2.
That the research presents no more than minimal risk of harm to
subjects, and involves no procedures, for which written consent
is normally required outside of the research context.
In
cases in which the documentation requirement is waived, the IRB
may require the investigator to provide subjects with a written
statement regarding the research.
IRB
Latitude to Approve a Consent Procedure that Alters or Waives some
or all of the Elements of Consent
§
46.116 - An IRB may approve a consent procedure, which does
not include, or which alters, some or all of the elements of informed
consent set forth in this section, or waive the requirements to
obtain informed consent, provided the IRB finds and documents that:
C:
1.The research or demonstration project is to be conducted by,
or subject to the approval of, state or local government officials,
and is designed to study, evaluate, or otherwise examine: (i) public
benefit or service programs; (ii) procedures for obtaining benefits
or services under those programs; (iii) possible changes in or alternatives
to those programs or procedures; or (iv) possible changes in methods
or levels of payment for benefits or services under those programs;
and
C:
2.The research could not practicably be carried out without
the waiver or alteration.
D:
1. The research involves no more than minimal risk to the subjects;
D:
2.The waiver or alteration will not adversely affect the rights
and welfare of the subjects;
D:
3.The research could not practicably be carried out without
the waiver or alteration; and
D:
4.Whenever appropriate, the subjects will be provided with additional
pertinent information after participation.
Special
Requirements - 45 CFR 46 Subpart D - Additional DHHS Protections
for Children Involved as Subjects in Research
Assent/Waiver
The
IRB shall determine that adequate provisions are made for soliciting
the assent of the children, when in the judgment of the IRB the
children are capable of providing assent. If the IRB determines
that the capability of some or all of the children is so limited
that they cannot reasonably be consulted, or that the intervention
or procedure involved in the research holds out a prospect of direct
benefit that is important to the health or well-being of the children,
and is available only in the context of the research, the assent
of the children is not a necessary condition for proceeding with
the research. Even where the IRB determines that the subjects are
capable of assenting, the IRB may still waive the assent requirement
under circumstances, in which consent may be waived in accord with
§46.116 of Subpart A.
Parents
The
IRB may find that the permission of one parent is sufficient for
research to be conducted under §46.404 or §46.405. Where research
is covered by §46.406 and §46.407, and permission is to be obtained
from parents, both parents must give their permission, unless one
parent is deceased, unknown, incompetent, or not reasonably available,
or when only one parent has legal responsibility for the care and
custody of the child.
If
the IRB determines that a research protocol is designed for conditions
or for a subject population, for which parental or guardian permission
is not a reasonable requirement to protect the subjects (for example,
neglected or abused children), it may waive the consent requirements
in Subpart A of this part and paragraph (b) of this section, provided
an appropriate mechanism for protecting the children who will participate
as subjects in the research is substituted, and provided further
that the waiver is not inconsistent with Federal, state or local
law.
Return to Table of Contents
TIPS
ON INFORMED CONSENT
The
process of obtaining informed consent must comply with the requirements
of 45 CFR 46.116. The documentation of informed consent must comply
with 45 CFR 46.117. The following comments may help in the development
of an approach and proposed language by investigators for obtaining
consent and its approval by IRBs:
Informed
consent is a process, not just a form. Information must be presented
to enable persons to voluntarily decide whether or not to participate
as a research subject. It is a fundamental mechanism to ensure respect
for persons through provision of thoughtful consent for a voluntary
act. The procedures used in obtaining informed consent should be
designed to educate the subject population in terms that they can
understand. Therefore, informed consent language and its documentation
(especially explanation of the study's purpose, duration, experimental
procedures, alternatives, risks, and benefits) must be written in
"lay language", (i.e. understandable to the people being
asked to participate). The written presentation of information is
used to document the basis for consent and for the subjects' future
reference. The consent document should be revised when deficiencies
are noted or when additional information will improve the consent
process.
Use
of the first person (e.g., "I understand that ...") can
be interpreted as suggestive, may be relied upon as a substitute
for sufficient factual information, and can constitute coercive
influence over a subject. Use of scientific jargon and legalese
is not appropriate. Think of the document primarily as a teaching
tool not as a legal instrument. Describe the overall experience
that will be encountered. Explain the research activity, how it
is experimental (e.g., a new drug, extra tests, separate research
records, or nonstandard means of management, such as flipping a
coin for random assignment or other design issues). Inform the human
subjects of the reasonably foreseeable harms, discomforts, inconvenience
and risks that are associated with the research activity. If additional
risks are identified during the course of the research, the consent
process and documentation will require revisions to inform subjects
as they are recontacted or newly contacted.
Describe
the benefits that subjects may reasonably expect to encounter. There
may be none other than a sense of helping the public at large. If
payment is given to defray the incurred expense for participation,
it must not be coercive in amount or method of distribution.
Describe
any alternatives to participating in the research project. For example,
in drug studies the medication(s) may be available through their
family doctor or clinic without the need to volunteer for the research
activity.
The
regulations insist that the subjects be told the extent to which
their personally identifiable private information will be held in
confidence. For example, some studies require disclosure of information
to other parties. Some studies inherently are in need of a Certificate
of Confidentiality which protects the investigator from involuntary
release (e.g.,subpoena) of the names or other identifying characteristics
of research subjects. The IRB will determine the level of adequate
requirements for confidentiality in light of its mandate to ensure
minimization of risk and determination that the residual risks warrant
involvement of subjects.
If
research-related injury (i.e. physical, psychological, social, financial,
or otherwise) is possible in research that is more than minimal
risk (see 45 CFR 46.102[g]), an explanation must be given of whatever
voluntary compensation and treatment will be provided. Note that
the regulations do not limit injury to "physical injury".
This is a common misinterpretation.
The
regulations prohibit waiving or appearing to waive any legal rights
of subjects. Therefore, for example, consent language must be carefully
selected that deals with what the institution is voluntarily willing
to do under circumstances, such as providing for compensation beyond
the provision of immediate or therapeutic intervention in response
to a research-related injury. In short, subjects should not be given
the impression that they have agreed to and are without recourse
to seek satisfaction beyond the institution's voluntarily chosen
limits.
The
regulations provide for the identification of contact persons who
would be knowledgeable to answer questions of subjects about the
research, rights as a research subject, and research-related injuries.
These three areas must be explicitly stated and addressed in the
consent process and documentation.
Furthermore,
a single person is not likely to be appropriate to answer questions
in all areas. This is because of potential conflicts of interest
or the appearance of such. Questions about the research are frequently
best answered by the investigator(s). However, questions about the
rights of research subjects or research-related injuries (where
applicable) may best be referred to those not on the research team.
These questions could be addressed to the IRB, an ombudsman, an
ethics committee, or other informed administrative body. Therefore,
each consent document can be expected to have at least two names
with local telephone numbers for contacts to answer questions in
these specified areas.
The
statement regarding voluntary participation and the right to withdraw
at any time can be taken almost verbatim from the regulations (45
CFR 46.116[a][8]). It is important not to overlook the need to point
out that no penalty or loss of benefits will occur as a result of
both not participating or withdrawing at any time. It is equally
important to alert potential subjects to any foreseeable consequences
to them should they unilaterally withdraw while dependent on some
intervention to maintain normal function.
Don't
forget to ensure provision for appropriate additional requirements
which concern consent. Some of these requirements can be found in
sections 46.116(b), 46.205(a)(2), 46.207(b), 46.208(b), 46.209(d),
46.305(a)(5-6), 46.408(c), and 46.409(b). The IRB may impose additional
requirements that are not specifically listed in the regulations
to ensure that adequate information is presented in accordance with
institutional policy and local law. Revised 3/16/93
Return to Table of Contents
Last
Updated August 17, 2006
|